Article
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
Journal of viral hepatitis - 1 May 2016
Ahn S H, Lim Y S, Lee K S, Paik S W, Lee Y J, Jeong S H, Kim J H, Yoon S K, Yim H J, Tak W Y, Han S Y, Yang J C, Mo H, Mathias A, Han L, Knox S J, Brainard D M, Kim Y J, Byun K S, Kim Y S, Heo J, Han K H
Abstract excerpt
In Korea, patients with chronic hepatitis C virus (HCV) infection are typically treated with pegylated interferon-alpha plus ribavirin, but interferons are contraindicated in many patients and are often poorly tolerated, particularly by the elderly and those with advanced liver disease. No interferon-free treatment regimens are approved in Korea. Sofosbuvir is an oral nucleotide analog inhibitor of the HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.